Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 9 Issue 6, June 2003

Advances in angiogenesis are leading to new therapies for ischemic injury and new approaches to treat cancer, blindness and other pathological disorders. On pages 653-725 of this issue, we present eight reviews in a special focus featuring the latest developments in angiogenesis research and its clinical applications. The reviews, and additional editorial content, are free to registered users on our website until 31 July 2003. The cover image depicts a stylized electron micrograph of vessels in the normal rat microvasculature.

Volume 9 Issue 6

Subscribe

Editorial

Top of page ⤴

News

Top of page ⤴

Correspondence

Top of page ⤴

Book Review

Top of page ⤴

News & Views

  • Autoimmunity is suspected to contribute to the formation of atherosclerotic plaques. Studies in mice suggest that this response may instead be protective—and that it may be enhanced with a vaccine (pages 736–743).

    • Noel Rose
    • Marina Afanasyeva
    News & Views

  • Vaccines using DNA for priming and recombinant modified vaccinia Ankara virus (MVA) for boosting have shown great promise in preclinical models. Now, this novel protocol appears effective in humans (pages 729–735).

    • Harriet L Robinson
    News & Views

  • Mutations in the gene that encodes nuclear lamins A and C cause a host of diseases, ranging from dilated cardiomyopathy to lipid disorders. The aging syndrome, Hutchinson-Gilford progeria, is now added to the list.

    • Robert A Hegele
    News & Views

  • Is diabetes a disease of the central nervous system? New data point in that direction. Alterations of the levels of long chain fatty acids in the hypothalamus are now shown to influence glucose homeostasis (pages 756–761).

    • Joel K Elmquist
    • Jacob N Marcus
    News & Views

  • T cells are recruited into the battle against pathogens by interaction with professional antigen-presenting cells (APCs). A new study shows that this recruitment phase is short and terminates when newly activated T cells kill the activating APCs.

    • David C Tscharke
    • Jonathan W Yewdell
    News & Views

  • Interleukin (IL)-2 can shrink tumors in patients with refractory melanoma and renal cancer, two of the deadliest types of solid tumors, but the use of IL-2 is limited by its high toxicity. A new drug reduces the side effects in mouse models and boosts the tumor-busting capacity of IL-2 (pages 750–755).

    • Jeffrey A Sosman
    • James W Mier
    News & Views
Top of page ⤴

Review Article

Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Technical Report

Top of page ⤴

On the Market

Top of page ⤴

Focus

  • A joint web focus between Nature Medicine and Nature Reviews Cancer.

    Focus
Top of page ⤴

Search

Advanced search

Quick links